Roquefort Therapeutics (LSE:ROQ) Pre-Tax Income : £-1.70 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Roquefort Therapeutics's pretax income for the six months ended in Jun. 2024 was £-0.70 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was £-1.70 Mil. Roquefort Therapeutics's pretax margin was %.

During the past 3 years, Roquefort Therapeutics's highest Pretax Margin was -966.00%. The lowest was -966.00%. And the median was -966.00%.

Roquefort Therapeutics Pre-Tax Income Historical Data

The historical data trend for Roquefort Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Pre-Tax Income Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Pre-Tax Income

-1.63

-1.93

Roquefort Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Pre-Tax Income	Get a 7-Day Free Trial			-0.76	-0.87	-0.94	-1.00	-0.70

Competitive Comparison of Roquefort Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Roquefort Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roquefort Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Roquefort Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Roquefort Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.934	+	0	+	0	+	0.001	+	0.0010000000000001
	=	-1.93

Roquefort Therapeutics's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.678	+	0	+	-0.014	+	0	+	-0.011
	=	-0.70

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-1.70 Mil.

Roquefort Therapeutics (LSE:ROQ) Pre-Tax Income Explanation

Roquefort Therapeutics's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-0.703	/	0
	=	%

During the past 3 years, Roquefort Therapeutics's highest Pretax Margin was -966.00%. The lowest was -966.00%. And the median was -966.00%.

Roquefort Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines